{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.6","upperLimit":"60.3","value":"41.7"},{"groupId":"OG001","lowerLimit":"18.9","upperLimit":"92.4","value":"60.0"},{"groupId":"OG002","lowerLimit":"8.7","upperLimit":"60.7","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"Complete response based on the modified NCCN criteria was defined as: less than 5% blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets \\>100\\*10\\^9 cells/L and ANC \\>1.0\\*10\\^9 cells/L. This outcome measure was planned to be analyzed for specified arms only.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed/refractory T-cell ALL received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and Cycle 1 Days 15, and 22 (CNS negative participants);for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV infusion once on Day 1; vincristine 1.5 mg/m\\^2 IV injection/infusion once weekly on Days 1, 8, 15 and 22 on Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Day 1 to 28 on Cycle 1; peg-asparaginase 2500 units per meter square (U/m\\^2) as intramuscular (IM) injection/IV infusion on Days 2, 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 2 Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide IV 1 g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/subcutaneous (SC) on Day 16 to 19 and Days 23 to 26; 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.9 months).","id":"OG000","title":"Cohort 2: T-Cell ALL (1-17 Years)"},{"description":"Participants with relapsed/refractory T-cell ALL in Cycle 1 received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and on Cycle 1 Days 15 and 22 (CNS negative participants); for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV once on Day 1 of Cycle 1; vincristine 1.5 mg/m\\^2 IV injection/infusion once weekly on Days 1, 8, 15 and 22 of Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Days 1 to 28 and peg-asparaginase 2500 U/m\\^2 as IM injection/IV infusion on Days 2 and 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg:\\>=9 years on Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide 1g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/SC on Days 16 to 19 and Days 23 to 26; and 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.1 months).","id":"OG001","title":"Cohort 2: T-Cell ALL (18-30 Years)"},{"description":"Participants with relapsed/refractory T-cell LL in Cycle 1 received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg: \\>=9 years on Cycle 1 Day 1 (all participants) and on Cycle 1 Days 15 and 22 (CNS negative participants); for CNS positive participants, along with MTX, HC/ARA-C was administered per local standard practice; daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; doxorubicin 60 mg/m\\^2 IV once on Day 1 of Cycle 1; vincristine 1.5 mg/m\\^2 IV injection/infusion weekly on Days 1, 8, 15 and 22 of Cycle 1; prednisone 40 mg/m\\^2 as 2 doses (20 mg/m\\^2 per dose) orally daily on Days 1 to 28 and peg-asparaginase 2500 U/m\\^2 as IM injection/IV infusion on Days 2 and 16 of Cycle 1. In Cycle 2, participants received intrathecal MTX 8 mg: 1 to \\<2 years, 10 mg: 2 to \\<3 years, 12 mg: 3 to \\<9 years and 15 mg:\\>=9 years on Days 2 and 15 (CNS negative participants); MTX, HC/ARA-C was administered by on Days 2 and 15 per local standard practice (CNS positive participants); daratumumab 16 mg/kg IV infusion weekly on Days 1, 8, 15 and 22; MTX 5 g/m\\^2 as IV once on Day 2, cyclophosphamide 1g/m\\^2 once on Day 15; cytarabine 75 mg/m\\^2 IV/SC on Days 16 to 19 and Days 23 to 26; and 6-mercaptopurine 60 mg/m\\^2 orally daily on Days 15 to 28 (maximum duration: 2.3 months).","id":"OG002","title":"Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)"}],"paramType":"NUMBER","populationDescription":"The all treated analysis set included all enrolled participants who received at least 1 dose of daratumumab.","reportingStatus":"POSTED","timeFrame":"End of Cycle 1 (that is, up to 28 days)","title":"Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}